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Summary: Consumptive coagulopathy and disseminated intravascular coagulation can be observed in rats exposed
to 4 ata of oxygen. These events clearly precede the death of the animal and appear to be initiated by an activation
of coagulation factor XII (ffageman). The onset and the extent of consumptive coagulopathy are greatly enhanced
by a single and low intravenous dose of lead acetate. Mechanisms of activation of the intrinsic coagulation system
and its role in oxygen toxicity are being discussed.
Verbrauchskoagulopathie als biochemischer Mechanismus für die Toxizität von Sauerstoff
und seine Verstärkung durch Blei (Unionen
Zusammenfassung: Werden Ratten einem Sauerstoff druck von 4 ata ausgesetzt, können Verbrauchskoagulopathie
und disseminierte intravaskuläre Gerinnung beobachtet werden. Diese Erscheinungen sind deutliche Vorzeichen
des Todes der Tiere und scheinen durch eine Aktivierung von Gerinnungsfaktor XII [Hageman] ausgelöst zu werden.
Das Einsetzen und das Ausmaß der Verbrauchskoagulopathie werden durch eine geringe intravenöse Einzelgabe von
Bleiacetat erheblich verstärkt. Der Aktivierungsmechanismus des intrinsic-Gerinnungssystems und seine Bedeutung
für die Toxizität von Sauerstoff werden diskutiert.
Introduction
Man and many animals, when exposed to oxygen
partial pressures (pO2) greater than that of air at sea
level, will suffer from various toxic effects of this
exposure. Since Paul Berfs original demonstration in
1878, these effects are summarized as "oxygen toxicity"
(1). They are known to become more severe when either
the pQ2 or the duration of exposure are increased and
are eventually leading to death. Oxygen toxicity may
indeed have the potential to affect most cells, tissues
and organs (2). However, it should be emphasized that
the low solubility of oxygen in water when combined
with the physical chemistry and shape of the hemo-
globin-oxygen equilibrium curve may severely reduce
the actual exposure of many cells and tissues to ex-
ceedingly high pQ2 values. Exceptional in this respect
are, besides skin and eyes* tihe tissues of the respiratory
tract including the lungs, the cells arid components of
blood and blood plasma, and the endothelial linings of
the arterial blood Vessels. These tissues will essentially
equilibrate with the 02 of the breathing gas. They
may therefore provide both primary and early target
sites for a progressing chain of cellular damage in oxy-
gen toxicity. Furthermore, such primary damage may
either by itself or by its involvement of other tissues lead
. to death. " „
More recently it has been reported that a single and low
intravenous dose of lead(II) ions (Pb2+) can drastically ·
shorten the survival time of rats exposed to increased
pO2 (3,4). The mechanism of this synergistic effect of
lead ions and 02 was first poorly understood; particularly,
since several physiological and biochemical systems and
functions failed to reveal any significant changes (4).
Subsequent studies, however, disclosed an activation of
the intrinsic coagulation pathway of the blood plasma to
be synergistically enhanced by lead ions and increased
p02 leading to consumptive coagulopathy and dissemi-
nated intravascular coagulation (5). In addition, it was
shown that the presence of a complete and factor com-
petent intrinsic coagulation cascade was essential for
this synergistic effect and that factor XII activity ap-
peared to be of particular importance in the lead-en-
hanced development of consumptive coagulopathy. .
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The present report will extend previous observations to
substantially increased p02 values and will discuss bio-
chemical mechanisms by which Pb2+ and 02 enhance
each others' activities synergistically.
Materials and Methods
Femoral cutdowns were performed on male Sprague-Dawley
rats (200 ± 20 g; NMRI strain) under light ether anesthesia. Ten
mg of lead acetate (PbAc2) or equimolar sodium acetate (NaAc)
dissolved in deionized H20 were given as a single i. v. injection.
Groups of 6 animals were placed in a small hyperbaric animal
chamber (Bethlehem) containing soda lime asCO2 scrubber.
The chamber was flushed for 5 min with 100% O2 at 1 ata and
was then pressurized to 4 ata over a 3 min period. Subsequently
it was vented with 02 at a 50 l per min flow rate for 5 min
which was then reduced to a maintenance vent rate of 1 1 per
min. Temperature was maintained at 22 ± 2 °C.
Blood samples were obtained by cardiac puncture of properly
decompressed animals (0.031 ata/s) under light ether anesthesia
using siliconized needles and plastic syringes. Introduction of
tissue thromboplastin was carefully avoided and initially sampled
blood always discarded.
Coagulation assays were performed in the Clotek system (Hy-
land). Prothrombin times (PT) and activated partial thrombo-
plastin times (APTT) were determined using standard techni-
ques (6) and standard reagents (Dade; Hyland)
The activities of coagulation factors V, VII, VIII and Xtt were
determined with factor deficient human plasma (Dade, Sera-
Tech) using standard curves developed for the factor activities
of rat plasma based on pooled, titrated rat plasma with
0.0284 mol/1 sodium barbital in 0.125 mol/1 NaCl, pH = 7.35
as diluent. All assays were performed in triplicate.
Factor XII activation was determined as spontaneous clotprompt-
ing activity of non-activated rat plasma in factor XII deficient
human plasma using the methods of Cochrane & Wuepper (7).
Fibrin monomers (FM) were assayed by the protamine sulfate
test of Niewiarowski & Gurevich (8). Fibrinogen/fibrin degrada-
tion products (FDP) were determined using the staphyloeoccal
clumping test (9).
All chemicals were A. R. grades or otherwise of the highest
purity available (Mallinckrodt, Baker).
Results
The exposure of rats that had been injected 18 h earlier
with sodium acetate to 4 ata of 100%02 results in a
gradual prolongation of both prothrombin time and
activated partial thromboplastin time values of the
blood plasma obtained from decompressed animals
(tab. 1). These increases, although already apparent
after as short a hyperbaric exposure time as 60 min,
became statistically significant after 90 min of exposure.
However, neither 60 nor 90 min of exposure time
resulted in detectable levels of fibrin monomers (FM)
orfibrinogen/fibrin degradation products (FDP) in any
of the animals of the sodium acetate groups (tab. 1).
Those animals that were given a single injection of lead
acetate 18 h prior to their exposure to 4 ata 02 showed
significantly prolonged prothrombin times and activated
partial thromboplastin times at 60 min exposure time
which became more prolonged with a further in-
crease of the exposure to 90 min (tab. 1). Moreover,
the treatment with Pb2+ resulted in an appearance
of fibrin monomers in 50 percent of the animals
at 60 min and in almost 90 percent at 90 min of
hyperbaric O2 exposure (tab. 1). Fibrinogen/fibrin
degradation products could also be detected in all ani-
mals of this group at both exposure times and at plasma
concentrations exceeding 40 mg/1. It should be noted
that the absolute survival times of the animals of the
sodium acetate groups were 265 ± 76 min and of the
lead acetate groups 146 ± 35 min respectively.
These results suggested an activation of the coagula-
tion system to occur as an early response of rats to an
exposure to 4 ata ρΟ2 which could also be enhanced
by Pb2+. Consequently, the plasma activities of coagula-
tion factors XII, VIII, VII and V were determined in
both groups of animals at both exposure times; i. e.,
60 and 90 min. It can be seen in figure 1 that an in-
creased time of exposure to a p02 of 4 ata results in
decreased activities of all coagulation factors examined.
Furthermore, a significant enhancement of this decrease
in factor activities resulting from the administration of
lead acetate was evident at both, 60 and 90 min of ex-
posure (fig. 1). These observations seem to confirm an
activation of the intrinsic coagulation system by hyper-
baric 02 which can be greatly accelerated by a treat-
ment with lead acetate and which leads to a rapid onset
of consumptive coagulopathy.
Additional evidence for disseminated intravascular
coagulation with a formation of microthrombi and
fibrin deposits was obtained from electron-microscopic
examination of various tissues and organs of animals
after their exposure to 4 ata 02. Particularly the animals
of the Pb2+ treated groups produced persistently .pic-
tures like those of figure 2 which shows intravascular
fibrin deposits and microthrombi formation in the lungs
of a Pb2+ treated rat after 90 min of exposure to 4 ata
pO2. It should be mentioned that the frequency with
which such pictures were observed iil various organs of
animals of the different experimental groups coincided
well with the .quantitative progression of all observed
changes in the blood coagulation system of the respective
groups.
Finally, it is shown in table 2 that, particularly in Pb2+
treated animals, an activation of coagulation factor XII
(Hageman) can be demonstrated after an exposure to
4 ata of 02 of only 30 min. This activation of factor XII,
the triggering factor of the intrinsic coagulation cascade,
was determined as elotpromoting activity of the rat
plasma in Hageman factor deficient human plasma and
was expressed as that fraction (in %) of total factor XII
activity which was spontaneously activated in vivo due
to treatment and exposure of the animals. Such activa-
tion of factor XII would therefore indicate a hyper-coagu^
lative state of the blood plasma* It would also point at
Hageman factor as a primary and common action site
for lead ions and hyperbaric O2.·
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Tab. 1. Effect of lead acetate and 4 ata 02 on prothrombin time (PT), activated partial thromboplastin time (APTT), fibrin mono-
mers (FM), and fibrin degradation products (FDP) in rats.
The number of animals per each experimental group was 24. Controls consisted of sodium acetate, lead acetate and no treat-
ment groups all of which produced similar values. The percentages of animals showing positive FM and FDP response are
given in parentheses. All PT and APTT values are given as means ± standard deviations. The absolute survival time of the






















































Tab. 2. The in vivo activation of Factor XII (Hagemari) in rats
exposed to 4 ata O2 with or without lead acetate treat-
ment.
The number of animals in each group was 1 2. Controls
include sodium acetate and lead acetate groups. Factor
activity represents spontaneous in vivo activation as
percentage of chemically in vitro activated total factor
activity.
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Fig. 1. The effects of lead acetate and/or exposure to 4 ata 02
for 60 and 90 min on coagulation factors XII, VIII, VII
and V in rats.
The slanted numbers indicate the exact percentage of
factor activities; the bars represent standard errors. The
number of animals in each group was 24. Exposure times:
(a) = 60 min; (b) = 90 min, E2 - lead acetate, D = sodium
acetate.
Discussion
In view of previous observations, none of the findings
reported here are completely unexpected. In fact, they
appear to be logical extensions of earlier data (5) which
they confirm at increased pU2 values and decreased
exposure times and with which they are in agreement.
Consequently, reference alone (5) may suffice in the
context of this report and may thus provide room for
the discussion of some additional consequences of
these experiments not previously touched upon.
For example, the rapid activation and subsequent con-
sumption of factor XII in animals exposed to 4 ata of
02 and the acceleration of these events by lead ions
indicate not only an enhancing effect on one component
of the intrinsic coagulation system but point also at a
common primary action site in the blood plasma. It is
therefore interesting to recall that the plasma of animals
breathing hyperbaric Oa belongs to the few "tissues"
that are indeed in equilibrium with high Oa pressures.
Furthermore, blood provides, at least initially, most of
the binding sites for which intravenous Pb2+ has
extremely high affinities. Besides inorganic phosphate,
these sites consist of sulfhydryl and phosphoryl groups
of proteins (10) and their binding of Pb2* may result
in changes of protein function and structure. For coagula-
tion factor XII this seems to result in a modified form *
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Fig. 2. Electron-micrographs of ultra-thin sections of lungs of lead acetate treated rats exposed to 4 ata Q2 f°r 90 mm·
The magnifications are: a = 70,000-fold; b = 17,500-fold. The following abbreviations are used: e = erythrocyte; f = fibrin;
p = blood platelet; w = white blood cell.
that is not only readily activated by bacterial lipopoly-
saccharides (11), but also by 02 at partial pressures
exceeding those of air at 1 ata. The exact chemical
mechanism by which such different chemical entities as
Pb2+ and 02 act on a protein is not yet known. How-
ever, hyperbaric 02 establishes its biochemical activities
through oxidative and auto-oxidative (peroxidative)
reactions which may also involve functional groups of
a Pb2+ modified protein of the Hageman factor leading
to its activation.
At present it is difficult to assess what effects, if any,
endothelial cells which may have been damaged by
Pb2+ and 02 could have on the biochemical mechanics
of an activation of the intrinsic coagulation system. How-
ever, the observed early activation of factor XII together
with the general pattern of subsequent factor consump-
tion in the development of disseminated intravascular
coagulation suggest this contribution to be of rather
limited significance. Yet, as a possibility it should not
be excluded completely.
Finally, if an activation of the intrinsic coagulation
pathway with consumptive coagulopathy and dissemi-
nated intravascular coagulation is indeed an early and
essential phase in the establishment of oxygen toxicity,
there are at least two interesting biological consequences
that would follow:
(i) factor XII deficient animals which can not activate
the intrinsic coagulation system should be quite resistant
to hyperbaric 02;
(ii) animals that, in the course of their physiological
activities, expose themselves to increased pulmonary
p02 values should be factor XII deficient.
A comparison of the mean survival times of several
animal species in 100% 02 (12) and the presence or
absence of factor XII activity (tab. 3) permits indeed
the formation of two groups.
One group is resistant to hyperbaric 02 and lacks
Hageman factor while the other one with short 02
survival times shows Hageman factor activity. More-
over, animals that perform breathholding dives to con-
siderable excursion depths like whales and porpoises -
the sperm whale has been reported to dive to a depth
of 1000 m with 75 min of breathholding and the
porpoise to 305 m with 6 min of breathholding (13) —
are also factor XII deficient (14).
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~N. D. = not determined.
~~ + indicates Factor XII presence; - its absence.
These latter observations are clearly teleological in
nature and may be more a curiosity of comparative
biology. As such they may add little to this discussion
and may even distract from the more serious patho-
physiological consequences of the experimental data
of this report. However, the growing use of hyperbaric
oxygen in respirators, and even as treatment modality
in hyperbaric chambers as well as the role of hyper-
baric 02 as an occupational health hazard potentially
affecting tunnel workers and divers attributes new
importance to all facets of oxygen toxicity including
those published here.
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